DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY

Markus Fridén,; K. Vanaja,; Vrinda N. Nandi,

doi:10.1515/DMDI.2006.21.3-4.163

Home Medicine DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY

Article

Licensed

Unlicensed Requires Authentication

DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY

, and

Published/Copyright: June 1, 2006

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Drug Metabolism and Drug Interactions Volume 21 Issue 3-4

MLA
APA
Harvard
Chicago
Vancouver

MLA
APA
Harvard
Chicago
Vancouver

Fridén,, Markus, Vanaja,, K. and Nandi,, Vrinda N.. "DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY" Drug Metabolism and Drug Interactions, vol. 21, no. 3-4, pp. 163-186. https://doi.org/10.1515/DMDI.2006.21.3-4.163

Fridén,, M., Vanaja,, K. & Nandi,, V. (). DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY. Drug Metabolism and Drug Interactions, 21(3-4), 163-186. https://doi.org/10.1515/DMDI.2006.21.3-4.163

Fridén,, M., Vanaja,, K. and Nandi,, V. () DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY. Drug Metabolism and Drug Interactions, Vol. 21 (Issue 3-4), pp. 163-186. https://doi.org/10.1515/DMDI.2006.21.3-4.163

Fridén,, Markus, Vanaja,, K. and Nandi,, Vrinda N.. "DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY" Drug Metabolism and Drug Interactions 21, no. 3-4 (): 163-186. https://doi.org/10.1515/DMDI.2006.21.3-4.163

Fridén, M, Vanaja, K, Nandi, V. DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY. Drug Metabolism and Drug Interactions. ;21(3-4): 163-186. https://doi.org/10.1515/DMDI.2006.21.3-4.163

Copy

Copied to clipboard

BibTeX EndNote RIS

Published Online: 2006-06

You are currently not able to access this content.

Articles in the same Issue

CONTENTS
THE INFLUENCE OF P-GLYCOPROTEIN ON CEREBRAL AND HEPATIC CONCENTRATIONS OF NORTRIPTYLINE AND ITS METABOLITES
DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY
IN VITRO STUDIES ON QUETIAPINE METABOLISM USING THE SUBSTRATE DEPLETION APPROACH WITH FOCUS ON DRUG-DRUG INTERACTIONS
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSARs) WITHIN CYTOCHROMES P450 2B (CYP2B) SUBFAMILY ENZYMES: THE IMPORTANCE OF LIPOPHILICITY FOR BINDING AND METABOLISM
VARIATIONS IN CONTENT OF ACTIVE INGREDIENTS CAUSING DRUG INTERACTIONS IN GRAPEFRUIT JUICE PRODUCTS SOLD IN CALIFORNIA
COMPARATIVE PROTEOMICS ANALYSIS OF DIFFERENTIALLY EXPRESSED PHOSPHOPROTEINS IN ADULT RAT VENTRICULAR MYOCYTES SUBJECTED TO DIAZOXIDE PRECONDITIONING
Index

Search journal Search the content of this journal

https://doi.org/10.1515/DMDI.2006.21.3-4.163

Articles in the same Issue

CONTENTS
THE INFLUENCE OF P-GLYCOPROTEIN ON CEREBRAL AND HEPATIC CONCENTRATIONS OF NORTRIPTYLINE AND ITS METABOLITES
DRUG-DRUG INTERACTIONS OF ANTI-INFECTIVE DRUGS: UTILITY OF FLUORESCENCE CYP INHIBITION ASSAYS IN DRUG DISCOVERY
IN VITRO STUDIES ON QUETIAPINE METABOLISM USING THE SUBSTRATE DEPLETION APPROACH WITH FOCUS ON DRUG-DRUG INTERACTIONS
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSARs) WITHIN CYTOCHROMES P450 2B (CYP2B) SUBFAMILY ENZYMES: THE IMPORTANCE OF LIPOPHILICITY FOR BINDING AND METABOLISM
VARIATIONS IN CONTENT OF ACTIVE INGREDIENTS CAUSING DRUG INTERACTIONS IN GRAPEFRUIT JUICE PRODUCTS SOLD IN CALIFORNIA
COMPARATIVE PROTEOMICS ANALYSIS OF DIFFERENTIALLY EXPRESSED PHOSPHOPROTEINS IN ADULT RAT VENTRICULAR MYOCYTES SUBJECTED TO DIAZOXIDE PRECONDITIONING
Index